Allergiplex

Apis Mellifica, Pulmo Anaphylactica, Pollantinum


Seroyal Usa
Human Otc Drug
NDC 62106-1400
Allergiplex also known as Apis Mellifica, Pulmo Anaphylactica, Pollantinum is a human otc drug labeled by 'Seroyal Usa'. National Drug Code (NDC) number for Allergiplex is 62106-1400. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Allergiplex drug includes Apis Mellifera - 15 [hp_C]/1 Bee Pollen - 30 [hp_C]/1 Histamine - 15 [hp_C]/1 . The currest status of Allergiplex drug is Active.

Drug Information:

Drug NDC: 62106-1400
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Allergiplex
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Apis Mellifica, Pulmo Anaphylactica, Pollantinum
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Seroyal Usa
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:APIS MELLIFERA - 15 [hp_C]/1
BEE POLLEN - 30 [hp_C]/1
HISTAMINE - 15 [hp_C]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:SUBLINGUAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 09 Feb, 2015
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 10 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Seroyal USA
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000185021
N0000175629
N0000184306
N0000185001
M0000728
M0002274
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:7S82P3R43Z
3729L8MA2C
820484N8I3
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Standardized Insect Venom Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Increased IgG Production [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Bee Venoms [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Bee Venoms [CS]
Cell-mediated Immunity [PE]
Increased Histamine Release [PE]
Increased IgG Production [PE]
Standardized Insect Venom Allergenic Extract [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
62106-1400-01 BLISTER PACK in 1 BOX (62106-1400-0) / 10 TABLET in 1 BLISTER PACK09 Feb, 2015N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Uses for the temporary relief of seasonal allergy symptoms such as: watery eyes runny nose

Product Elements:

Allergiplex apis mellifica, pulmo anaphylactica, pollantinum apis mellifera apis mellifera histamine histamine bee pollen bee pollen magnesium stearate xylitol carboxymethylcellulose sodium lactose monohydrate

Indications and Usage:

Uses for the temporary relief of seasonal allergy symptoms such as: watery eyes runny nose directions adults and adolescents (12 years and older): at the first sign of symptoms, take one tablet daily allowing it to dissolve under the tongue. after the symptoms are gone, continue taking one tablet daily for three more days. repeat if symptoms reappear or if chronic, take one tablet weekly for four weeks prior to allergy season. children (under 12 years): take under the direction of your healthcare practitioner.

Warnings:

Warnings stop use and ask a doctor if symptoms persist or worsen. do not use if you have ever had an allergic reaction to this product or any of its ingredients. if pregnant or breastfeeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away.

Do Not Use:

Warnings stop use and ask a doctor if symptoms persist or worsen. do not use if you have ever had an allergic reaction to this product or any of its ingredients. if pregnant or breastfeeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away.

Dosage and Administration:

Directions adults and adolescents (12 years and older): at the first sign of symptoms, take one tablet daily allowing it to dissolve under the tongue. after the symptoms are gone, continue taking one tablet daily for three more days. repeat if symptoms reappear or if chronic, take one tablet weekly for four weeks prior to allergy season. children (under 12 years): take under the direction of your healthcare practitioner.

Overdosage:

In case of overdose, get medical help or contact a poison control center right away.

Package Label Principal Display Panel:

Ndc 62106-1400-0 unda plex allergiplex homeopathic preparation for the temporary relief of seasonal allergy symptoms. 10 tablets 62106-1400


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.